Member Info for Bennster

?? no it's not - it's 5p to buy right now...

no - this is normal retrace from traders... remember this thing has risen rapidly for a week or so.
It'll be choppy for a little bit but will stay above 5p

Thanks for posting

Now we've passed the magic 5p mark there could be volatility - now the Monecor warrants become profitable (and liable to be exercised) and all their placings from the back end of last year are green too.
Possibly choppy waters for a while as they drip some block sells in methinks, but equally this should ensure we don't drop below 5p for any length of time either as we have a new section of holders at this price.
When Monecor is cleared then the anchor is gone - things could get really exciting!

Once FAB have done one it has no choice but to rise, there's nobody left who can sell for a profit.
The challenge is just how far this needs to go just to get back to when they started to offload... 34p from 6 weeks ago is a long long way back without stellar news. And if that was due why are FAB chucking their shares away...?

Quality ramp mate.
Roll up, roll up! come and get 'em while they're hot!
Why would today be any different to the last 6 weeks - we still have no news and the testing was due to start by the end of Feb.

Well what a beautiful morning !!
Superbowl hangover is bad. Felt worse when I checked on my spreadbets, looks like Ukraine again.
Then I saw this :-)
SP target just got altered on the back of a second date - this is a material uptick for us. I'm targeting 20p now, unless 13:30 call has a nasty surprise placing. Exciting times.

Maybe so.
Or maybe not.
It's the arrival of that magic RNS with real £££ in it that will settle the debate one way or another. Here's hoping Alice and all the others flogging their shares away merrily are all wrong and we're going to be rich.

A great question - one we would love Alice to answer..................

Simply put there's been no news on the Paraytec tests UKbased.
We were led to believe it would take a couple of months and that was 6 months ago.
In the last 6 weeks a major shareholder has bailed.
Nothing negative or bashing here, just relaying what's changed
We all hope for some real news soon!

Readers here will be able to judge your last post. You don't want to hear anything that doesn't suit so you hide.
The Prof's tweet does NOT infer that the Paraytec test is relevant at all, it just says "Testing is here to stay"
It is not a statement of fact - it's his opinion. It does not say how much testing, when, where or who's test will be used.
I'm being kind by describing your effort to post it as confirmation bias - if it's deliberate then it's much worse.
We need real news, which will only come via an RNS, which needs to spell out some real £££ data. IF that comes we'll all be happy.
Enjoy your blinkers.

I promise you I don't put everything down at all and I don't want BRH to fail.
I do believe in keeping it real.
Clinging to vague tweets isn't keeping it real, we've seen far too much of this throughout the last 12 months on here.
BRH is an investment company - it's not in the least bit interested in saving the world from COVID - it's about making money. Enough of those who are close to the company have chosen to sell up in the last 6 weeks - just a reality, not a bash.
I still believe the benefit to come will be Phasefocus and perhaps other long term uses for the Paraytec work, like Sepsis and Bladder Cancer. Whenever you or anybody else has discussed these things I never bash - I often come here to agree.
Whenever I see basesless COVID ramps I will come back and call it out. If you'd like to see less of me pulling posts apart then stop and think before you post.
Have a super Sunday.

Relax Armagedon.
A group of evangelists including you have launched an "I told you so" chain on the back of the worlds' most vague and basic tweet - I'm entitled to point that out for what it is.
I didn't ask you to post vague tweets like this and make out that the world is a better place today.

We all know you'd dearly love me to disappear because I don't fit in with your schoolyard clique and I don't tow your narrative.

It does NOT say BRH's Paraytec test is working, or what type of covid testing is here to stay.
If he had tweeted "I like Trevor" some on here would be celebrating their multibagger from the rooftops. The confirmatory bias here is insane!
What we need, and many of us already know this, is a proper RNS that highlights positive sales, earnings, dividend or other material progress.

Again - I can't see what in that tweet signals all is good to go. It's a 5 word tweet and it's a general note on COVID....

Agree - the multiplier is the biggest variable here, and that's the beauty of investing. You say Tomayto and I say Tomahto....
At least both methods look better than SP now :-)
The calcs also highlight the real risk of dilution, which is why I care so much about it - it affects the split of earnings and also sentiment.

Yep - you are using EBT then, which is less generous than EBITDA.

I'd like to understand what you mean by earnings because I don't recognise it if it's not based on EBT. EBIT or EBITDA - see below:

Measures of Earnings
There are many measures and uses of earnings. Some analysts like to calculate earnings before taxes (EBT), also known as pre-tax income. Some analysts prefer to see earnings before interest and taxes (EBIT). Still, other analysts, mainly in industries with a high level of fixed assets, prefer to see earnings before interest, taxes, depreciation, and amortization, also known as EBITDA.
All three figures provide varying degrees of measuring profitability.
Earnings per Share
Earnings per share (EPS) is a commonly cited ratio used to show the company's profitability on a per-share basis. It is calculated by dividing the company's total earnings by the number of shares outstanding.
Price-to-Earnings
Earnings are also used to determine a key indicator known as the price-to-earnings (P/E) ratio.
The price-to-earnings ratio, calculated as share price divided by earnings per share, is used by investors and analysts to compare the relative values of companies in the same industry or sector.

On this basis using EBITDA is the most generous.... LVCG won't have any ENT as they have depreciated and amortised Bricklive investment and pay some interest on debt.

On an EBITDA of £1.6M, the earnings per share would be 1p and at a P/E of 10 that would mean 10p a share.

"Plus I base my calculations on Earnings and not EBITDA."

Just for clarity - the E in EBITDA stands for earnings.... that's what you should classically base P/E on.

2023 then becomes a key year - that does indeed have the potential to be better and help both shore up the balance sheet and also increase EBITDA.
What makes this sharer so attractive to me is that I could get in at such a level and if it's run prudently has great potential for not just one event but for years.
I would sympathise with anyone who got in at 20p + back before COVID.